Perspective Therapeutics (NYSE:CATX) Receives Outperform Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a report released on Friday morning,RTT News reports. Wedbush currently has a $11.00 target price on the stock.

A number of other research firms have also weighed in on CATX. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Royal Bank of Canada restated an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Oppenheimer cut their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Finally, UBS Group began coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.14.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $4.01 on Friday. Perspective Therapeutics has a 12-month low of $2.70 and a 12-month high of $19.05. The firm has a 50 day moving average of $3.68 and a 200 day moving average of $9.76.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million during the quarter. Sell-side analysts predict that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Insider Buying and Selling at Perspective Therapeutics

In related news, Director Heidi Henson acquired 25,975 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were acquired at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the completion of the transaction, the director now directly owns 25,975 shares in the company, valued at approximately $100,003.75. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Johan M. Spoor acquired 8,000 shares of the stock in a transaction dated Wednesday, December 4th. The stock was bought at an average cost of $3.77 per share, with a total value of $30,160.00. Following the completion of the purchase, the chief executive officer now directly owns 36,257 shares in the company, valued at approximately $136,688.89. The trade was a 28.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 67,570 shares of company stock worth $256,789 over the last 90 days. 3.52% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CATX. FMR LLC lifted its holdings in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after acquiring an additional 5,370,392 shares during the last quarter. Nicholson Wealth Management Group LLC purchased a new stake in Perspective Therapeutics in the 3rd quarter worth about $21,390,000. State Street Corp lifted its stake in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Hills Bank & Trust Co purchased a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $13,722,000. Finally, Janus Henderson Group PLC grew its stake in shares of Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after buying an additional 355,685 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.